Prostate cancer (PCa) is a major diagnosed cancer among men globally, and about 20% of
patients develop metastatic prostate cancer (mPCa) in the initial diagnosis. PCa is a typical …

Castration and androgen receptor (AR) pathway inhibitors induce profound and sustained
responses in advanced prostate cancer. However, the inevitable recurrence is associated …

Androgen deprivation therapy or ADT is one of the cornerstones of management of locally
advanced or metastatic prostate cancer, alongside radiation therapy. However, despite early …

The landscape of castration-resistant prostate carcinoma has changed completely in the last
few years, with the approval of four new agents with proven benefit in overall survival …

Simple Summary Prostate cancer can develop under hormone treatment and chemotherapy
from a castration-sensitive towards a castration-resistant into a drug resistant-tumor. The …

Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an
important challenge in the treatment of prostate cancer patients. Activation of alternative …

Targeting androgen receptor (AR) axis signaling by disrupting androgen-AR interactions
remains the primary treatment for metastatic prostate cancer. Unfortunately, all men develop …

Abstract Purpose: The PI3K/Akt/mTOR pathway is activated in most castration-resistant
prostate cancers (CRPC). Transcriptionally active androgen receptor (AR) plays a role in the …

Recent advances in the treatment of prostate cancer have resulted in improved outcomes,
including longer survival, but new options are needed for treating patients with castration …

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR)
signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal …